Jounce Therapeutics Reports Second Quarter 2019 Financial Results
August 07, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- Initiated Phase 2 EMERGE trial of vopratelimab - - Completed enrollment of Phase 1 trial of JTX-4014 - - Updated strategic collaboration and established new licensing agreement with...
Jounce Therapeutics to Announce Second Quarter 2019 Financial Results and Host Conference Call on Wednesday, August 7, 2019
July 31, 2019 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., July 31, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Announces Update on Strategic Collaboration with Celgene Corporation
July 23, 2019 16:00 ET
|
Jounce Therapeutics, Inc.
- Celgene licenses JTX-8064, resulting in $50.0 million upfront payment to Jounce - - Jounce retains full worldwide rights to vopratelimab, JTX‑4014 and all discovery programs - - Company to host...
Jounce Therapeutics Initiates Phase 2 EMERGE Study of Vopratelimab in Combination with Ipilimumab in Patients with Non-Small Cell Lung Cancer or Urothelial Cancer
June 18, 2019 08:00 ET
|
Jounce Therapeutics, Inc.
- Commenced patient enrollment in Phase 2 clinical trial of vopratelimab in combination with ipilimumab - - Preliminary efficacy and relationship to biomarker data expected in 2020 - CAMBRIDGE,...
Jounce Therapeutics to Present at Upcoming Investor Conferences in June
June 11, 2019 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., June 11, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports First Quarter 2019 Financial Results
May 08, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New data from vopratelimab and JTX-8064 presented at AACR 2019 - - On track to initiate new Phase 2 studies of vopratelimab - - Ended the quarter with $173.2 million in cash, cash equivalents and...
Jounce Therapeutics to Announce First Quarter 2019 Financial Results and Host Conference Call on Wednesday, May 8, 2019
May 01, 2019 08:00 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., May 01, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Presents Preclinical Data from JTX-8064 Program at the 2019 American Association for Cancer Research (AACR) Annual Meeting
April 03, 2019 08:02 ET
|
Jounce Therapeutics, Inc.
CAMBRIDGE, Mass., April 03, 2019 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
Jounce Therapeutics Reports Improved PFS and OS Associated with Vopratelimab (JTX-2011) Treatment Emergent Biomarker at the 2019 American Association for Cancer Research (AACR) Annual Meeting
April 02, 2019 13:02 ET
|
Jounce Therapeutics, Inc.
- Improved PFS and OS observed in patients treated with vopratelimab who have emergence of ICOS hi CD4 T cells compared to patients with ICOS lo CD4 T cells - - ICOS hi CD4 T cells demonstrate...
Jounce Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results
March 06, 2019 06:30 ET
|
Jounce Therapeutics, Inc.
- New data from two programs to be presented at AACR - - New Phase 2 studies to be initiated in 2019 supported by established safety from dose escalation cohorts of vopratelimab (JTX-2011), with...